{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T00:25:47Z","timestamp":1792801547379,"version":"4.5.0"},"reference-count":57,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bone"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1016\/j.bone.2025.117600","type":"journal-article","created":{"date-parts":[[2025,7,26]],"date-time":"2025-07-26T15:07:23Z","timestamp":1753542443000},"page":"117600","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"special_numbering":"C","title":["Treating osteoporosis with denosumab or bisphosphonates in the long term: facts, uncertainties and assumptions. A narrative review by the clinical action group of the European Calcified Tissue Society (ECTS)"],"prefix":"10.1016","volume":"200","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4576-3381","authenticated-orcid":false,"given":"Anda Mihaela","family":"Naciu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6808-0700","authenticated-orcid":false,"given":"Gaia","family":"Tabacco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1143-4926","authenticated-orcid":false,"given":"Andrea","family":"Palermo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6501-3692","authenticated-orcid":false,"given":"Maria P.","family":"Yavropoulou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1058-1307","authenticated-orcid":false,"given":"Tim","family":"Rolvien","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1071-2058","authenticated-orcid":false,"given":"Stella","family":"D'Oronzo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7292-2328","authenticated-orcid":false,"given":"John J.","family":"Carey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6599-8623","authenticated-orcid":false,"given":"Julien","family":"Paccou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6885-3953","authenticated-orcid":false,"given":"Willem","family":"Lems","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9624-6296","authenticated-orcid":false,"given":"Athanasios D.","family":"Anastasilakis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.bone.2025.117600_bb0005","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1080\/14656566.2020.1717468","article-title":"Combination and sequential treatment in women with postmenopausal osteoporosis","volume":"21","author":"Anastasilakis","year":"2020","journal-title":"Expert. Opin. Pharmacother."},{"issue":"24","key":"10.1016\/j.bone.2025.117600_bb0010","doi-asserted-by":"crossref","first-page":"2927","DOI":"10.1001\/jama.296.24.2927","article-title":"Effects of continuing or stopping alendronate after 5 years of treatment: the fracture intervention trial long-term extension (FLEX): a randomized trial","volume":"296","author":"Black","year":"2006","journal-title":"JAMA"},{"issue":"7","key":"10.1016\/j.bone.2025.117600_bb0015","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1016\/S2213-8587(17)30138-9","article-title":"10 years of denosumab treatment in postmenopausal women with osteoporosis: results from the phase 3 randomised FREEDOM trial and open-label extension","volume":"5","author":"Bone","year":"2017","journal-title":"Lancet Diabetes Endocrinol."},{"issue":"10","key":"10.1016\/j.bone.2025.117600_bb0020","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1359\/jbmr.0707onj","article-title":"American Society for, R. Mineral, Bisphosphonate-associated osteonecrosis of the jaw: report of a task force of the American Society for Bone and Mineral Research","volume":"22","author":"Khosla","year":"2007","journal-title":"J. Bone Miner. Res."},{"issue":"1","key":"10.1016\/j.bone.2025.117600_bb0025","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/jbmr.1998","article-title":"Atypical subtrochanteric and diaphyseal femoral fractures: second report of a task force of the American Society for Bone and Mineral Research","volume":"29","author":"Shane","year":"2014","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.bone.2025.117600_bb0030","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.bone.2017.08.003","article-title":"Discontinuation of Denosumab therapy for osteoporosis: A systematic review and position statement by ECTS","volume":"105","author":"Tsourdi","year":"2017","journal-title":"Bone"},{"issue":"5","key":"10.1016\/j.bone.2025.117600_bb0035","doi-asserted-by":"crossref","first-page":"1595","DOI":"10.1210\/jc.2019-00221","article-title":"Pharmacological Management of Osteoporosis in Postmenopausal Women: An Endocrine Society* Clinical Practice Guideline","volume":"104","author":"Eastell","year":"2019","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"2","key":"10.1016\/j.bone.2025.117600_bb0040","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1002\/jbmr.1494","article-title":"The effect of 3 versus 6 years of zoledronic acid treatment of osteoporosis: a randomized extension to the HORIZON-Pivotal Fracture Trial (PFT)","volume":"27","author":"Black","year":"2012","journal-title":"J. Bone Miner. Res."},{"issue":"5","key":"10.1016\/j.bone.2025.117600_bb0045","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1002\/jbmr.2442","article-title":"The effect of 6 versus 9 years of zoledronic acid treatment in osteoporosis: a randomized second extension to the HORIZON-Pivotal Fracture Trial (PFT)","volume":"30","author":"Black","year":"2015","journal-title":"J. Bone Miner. Res."},{"issue":"6","key":"10.1016\/j.bone.2025.117600_bb0050","doi-asserted-by":"crossref","first-page":"1769","DOI":"10.1007\/s00198-011-1793-9","article-title":"Long-term administration of quarterly IV ibandronate is effective and well tolerated in postmenopausal osteoporosis: 5-year data from the DIVA study long-term extension","volume":"23","author":"Bianchi","year":"2012","journal-title":"Osteoporos. Int."},{"issue":"6","key":"10.1016\/j.bone.2025.117600_bb0055","doi-asserted-by":"crossref","first-page":"1747","DOI":"10.1007\/s00198-011-1773-0","article-title":"Efficacy of monthly oral ibandronate is sustained over 5 years: the MOBILE long-term extension study","volume":"23","author":"Miller","year":"2012","journal-title":"Osteoporos. Int."},{"issue":"6","key":"10.1016\/j.bone.2025.117600_bb0060","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1007\/s00223-004-0286-7","article-title":"Seven years of treatment with risedronate in women with postmenopausal osteoporosis","volume":"75","author":"Mellstrom","year":"2004","journal-title":"Calcif. Tissue Int."},{"issue":"3","key":"10.1016\/j.bone.2025.117600_bb0065","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1002\/jbmr.5650110307","article-title":"Increased bone turnover in late postmenopausal women is a major determinant of osteoporosis","volume":"11","author":"Garnero","year":"1996","journal-title":"J. Bone Miner. Res."},{"issue":"3","key":"10.1016\/j.bone.2025.117600_bb0070","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1056\/NEJMoa2407031","article-title":"Fracture Prevention with Infrequent Zoledronate in Women 50 to 60 Years of Age","volume":"392","author":"Bolland","year":"2025","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.bone.2025.117600_bb0075","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1002\/jbmr.4453","article-title":"Bone Mineral Density and Bone Turnover 10Years After a Single 5mg Dose or Two 5-Yearly Lower Doses of Zoledronate in Osteopenic Older Women: An Open-Label Extension of a Randomized Controlled Trial","volume":"37","author":"Grey","year":"2022","journal-title":"J. Bone Miner. Res."},{"issue":"25","key":"10.1016\/j.bone.2025.117600_bb0080","doi-asserted-by":"crossref","first-page":"2407","DOI":"10.1056\/NEJMoa1808082","article-title":"Fracture Prevention with Zoledronate in Older Women with Osteopenia","volume":"379","author":"Reid","year":"2018","journal-title":"N. Engl. J. Med."},{"issue":"4","key":"10.1016\/j.bone.2025.117600_bb0085","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/S2213-8587(24)00003-2","article-title":"Duration of fracture prevention after zoledronate treatment in women with osteopenia: observational follow-up of a 6-year randomised controlled trial to 10 years","volume":"12","author":"Reid","year":"2024","journal-title":"Lancet Diabetes Endocrinol."},{"issue":"2","key":"10.1016\/j.bone.2025.117600_bb0090","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/S8756-3282(02)00946-8","article-title":"Long-term efficacy of risedronate: a 5-year placebo-controlled clinical experience","volume":"32","author":"Sorensen","year":"2003","journal-title":"Bone"},{"issue":"11","key":"10.1016\/j.bone.2025.117600_bb0095","doi-asserted-by":"crossref","first-page":"3367","DOI":"10.1210\/jc.2011-0412","article-title":"Effect of stopping risedronate after long-term treatment on bone turnover","volume":"96","author":"Eastell","year":"2011","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"14","key":"10.1016\/j.bone.2025.117600_bb0100","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1001\/jama.282.14.1344","article-title":"Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial, Vertebral Efficacy With Risedronate Therapy (VERT) Study Group","volume":"282","author":"Harris","year":"1999","journal-title":"JAMA"},{"issue":"3","key":"10.1016\/j.bone.2025.117600_bb0105","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1007\/s00198-007-0460-7","article-title":"Fracture risk remains reduced one year after discontinuation of risedronate","volume":"19","author":"Watts","year":"2008","journal-title":"Osteoporos. Int."},{"issue":"1","key":"10.1016\/j.bone.2025.117600_bb0110","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1359\/jbmr.090702","article-title":"Mineralization density distribution of postmenopausal osteoporotic bone is restored to normal after long-term alendronate treatment: qBEI and sSAXS data from the fracture intervention trial long-term extension (FLEX)","volume":"25","author":"Roschger","year":"2010","journal-title":"J. Bone Miner. Res."},{"issue":"6","key":"10.1016\/j.bone.2025.117600_bb0115","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1007\/s00223-004-0039-7","article-title":"Five years of treatment with risedronate and its effects on bone safety in women with postmenopausal osteoporosis","volume":"75","author":"Ste-Marie","year":"2004","journal-title":"Calcif. Tissue Int."},{"issue":"7","key":"10.1016\/j.bone.2025.117600_bb0120","doi-asserted-by":"crossref","first-page":"2498","DOI":"10.1210\/jc.2017-02669","article-title":"Effects of Long-Term Denosumab on Bone Histomorphometry and Mineralization in Women With Postmenopausal Osteoporosis","volume":"103","author":"Dempster","year":"2018","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"8","key":"10.1016\/j.bone.2025.117600_bb0125","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1359\/JBMR.040326","article-title":"Fracture Intervention Trial Long-Term Extension Research, Randomized trial of effect of alendronate continuation versus discontinuation in women with low BMD: results from the Fracture Intervention Trial long-term extension","volume":"19","author":"Ensrud","year":"2004","journal-title":"J. Bone Miner. Res."},{"issue":"12","key":"10.1016\/j.bone.2025.117600_bb0130","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1056\/NEJMoa030897","article-title":"Ten years\u2019 experience with alendronate for osteoporosis in postmenopausal women","volume":"350","author":"Bone","year":"2004","journal-title":"N. Engl. J. Med."},{"issue":"5","key":"10.1016\/j.bone.2025.117600_bb0135","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1002\/jbmr.11","article-title":"Efficacy of continued alendronate for fractures in women with and without prevalent vertebral fracture: the FLEX trial","volume":"25","author":"Schwartz","year":"2010","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.bone.2025.117600_bb0140","article-title":"Risk of hip, subtrochanteric, and femoral shaft fractures among mid and long term users of alendronate: nationwide cohort and nested case-control study","volume":"353","author":"Abrahamsen","year":"2016","journal-title":"BMJ"},{"issue":"8","key":"10.1016\/j.bone.2025.117600_bb0145","doi-asserted-by":"crossref","first-page":"3450","DOI":"10.1210\/jc.2019-00271","article-title":"Further Nonvertebral Fracture Reduction Beyond 3 Years for Up to 10 Years of Denosumab Treatment","volume":"104","author":"Ferrari","year":"2019","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.bone.2025.117600_bb0150","article-title":"Osteoporosis, bisphosphonates, and ocular inflammation","author":"Nouraeinejad","year":"2022","journal-title":"Eur. J. Ophthalmol."},{"issue":"5","key":"10.1016\/j.bone.2025.117600_bb0155","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.1210\/clinem\/dgab888","article-title":"Osteonecrosis of the Jaw and Antiresorptive Agents in Benign and Malignant Diseases: A Critical Review Organized by the ECTS","volume":"107","author":"Anastasilakis","year":"2022","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"2","key":"10.1016\/j.bone.2025.117600_bb0160","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1002\/jbmr.4472","article-title":"Risk of osteonecrosis of the jaw under denosumab compared to bisphosphonates in patients with osteoporosis","volume":"37","author":"Everts-Graber","year":"2022","journal-title":"J. Bone Miner. Res."},{"issue":"4","key":"10.1016\/j.bone.2025.117600_bb0165","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1016\/j.jocd.2013.09.018","article-title":"Understanding and communicating the benefits and risks of denosumab, raloxifene, and teriparatide for the treatment of osteoporosis","volume":"17","author":"Lewiecki","year":"2014","journal-title":"J. Clin. Densitom."},{"issue":"4","key":"10.1016\/j.bone.2025.117600_bb0170","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/j.jocd.2010.06.005","article-title":"Risk communication and shared decision making in the care of patients with osteoporosis","volume":"13","author":"Lewiecki","year":"2010","journal-title":"J. Clin. Densitom."},{"issue":"1","key":"10.1016\/j.bone.2025.117600_bb0175","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1007\/s00198-014-2900-5","article-title":"Residual effect after oral bisphosphonate treatment and healthy adherer effects--the Swedish Adherence Register Analysis (SARA)","volume":"26","author":"Strom","year":"2015","journal-title":"Osteoporos. Int."},{"issue":"1","key":"10.1016\/j.bone.2025.117600_bb0180","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1002\/jbmr.2708","article-title":"Managing Osteoporosis in Patients on Long-Term Bisphosphonate Treatment: Report of a Task Force of the American Society for Bone and Mineral Research","volume":"31","author":"Adler","year":"2016","journal-title":"J. Bone Miner. Res."},{"issue":"10","key":"10.1016\/j.bone.2025.117600_bb0185","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1038\/s41574-018-0087-0","article-title":"Clinical advantages and disadvantages of anabolic bone therapies targeting the WNT pathway","volume":"14","author":"Appelman-Dijkstra","year":"2018","journal-title":"Nat. Rev. Endocrinol."},{"issue":"6","key":"10.1016\/j.bone.2025.117600_bb0190","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1002\/jbmr.3110","article-title":"Clinical Features of 24 Patients With Rebound-Associated Vertebral Fractures After Denosumab Discontinuation: Systematic Review and Additional Cases","volume":"32","author":"Anastasilakis","year":"2017","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.bone.2025.117600_bb0195","article-title":"Fracture risk and management of discontinuation of denosumab therapy: a systematic review and position statement by ECTS","author":"Tsourdi","year":"2020","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"11","key":"10.1016\/j.bone.2025.117600_bb0200","doi-asserted-by":"crossref","first-page":"2112","DOI":"10.1002\/jbmr.4705","article-title":"Multiple vertebral fractures after denosumab discontinuation: FREEDOM and FREEDOM extension trials additional post hoc analyses","volume":"37","author":"Cosman","year":"2022","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.bone.2025.117600_bb0205","doi-asserted-by":"crossref","DOI":"10.1016\/j.bone.2020.115830","article-title":"Risk factors for vertebral fractures and bone loss after denosumab discontinuation: A real-world observational study","volume":"144","author":"Everts-Graber","year":"2021","journal-title":"Bone"},{"issue":"9","key":"10.1016\/j.bone.2025.117600_bb0210","doi-asserted-by":"crossref","first-page":"1717","DOI":"10.1002\/jbmr.4335","article-title":"The Swiss Denosumab Study, Fractures After Denosumab Discontinuation: A Retrospective Study of 797 Cases","volume":"36","author":"Burckhardt","year":"2021","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.bone.2025.117600_bb0215","doi-asserted-by":"crossref","DOI":"10.1016\/j.bone.2022.116498","article-title":"Effects of zoledronate on bone mineral density and bone turnover after long-term denosumab therapy: Observations in a real-world setting","volume":"163","author":"Everts-Graber","year":"2022","journal-title":"Bone"},{"issue":"10","key":"10.1016\/j.bone.2025.117600_bb0220","doi-asserted-by":"crossref","first-page":"e4155","DOI":"10.1210\/clinem\/dgab321","article-title":"The Duration of Denosumab Treatment and the Efficacy of Zoledronate to Preserve Bone Mineral Density After Its Discontinuation","volume":"106","author":"Makras","year":"2021","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"6","key":"10.1016\/j.bone.2025.117600_bb0225","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1007\/s00198-018-4460-6","article-title":"Effects of discontinuing oral bisphosphonate treatments for postmenopausal osteoporosis on bone turnover markers and bone density","volume":"29","author":"Naylor","year":"2018","journal-title":"Osteoporos. Int."},{"issue":"3","key":"10.1016\/j.bone.2025.117600_bb0230","doi-asserted-by":"crossref","first-page":"335","DOI":"10.7326\/M21-2512","article-title":"Comparative Fracture Risk During Osteoporosis Drug Holidays After Long-Term Risedronate Versus Alendronate Therapy\u202f: A Propensity Score-Matched Cohort Study","volume":"175","author":"Hayes","year":"2022","journal-title":"Ann. Intern. Med."},{"issue":"22","key":"10.1016\/j.bone.2025.117600_bb0235","doi-asserted-by":"crossref","first-page":"2048","DOI":"10.1056\/NEJMp1202619","article-title":"Bisphosphonates for osteoporosis--where do we go from here?","volume":"366","author":"Whitaker","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bone.2025.117600_bb0240","doi-asserted-by":"crossref","DOI":"10.1016\/j.bone.2021.116297","article-title":"Bisphosphonates and the risk of atypical femur fractures","volume":"156","author":"Black","year":"2022","journal-title":"Bone"},{"issue":"1","key":"10.1016\/j.bone.2025.117600_bb0245","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1111\/jcpt.13056","article-title":"Potential risks of rare serious adverse effects related to long-term use of bisphosphonates: An overview of systematic reviews","volume":"45","author":"Lu","year":"2020","journal-title":"J. Clin. Pharm. Ther."},{"issue":"12","key":"10.1016\/j.bone.2025.117600_bb0250","doi-asserted-by":"crossref","first-page":"2303","DOI":"10.1007\/s00198-020-05569-9","article-title":"Is a treat-to-target strategy in osteoporosis applicable in clinical practice? Consensus among a panel of European experts","volume":"31","author":"Thomas","year":"2020","journal-title":"Osteoporos. Int."},{"issue":"6","key":"10.1016\/j.bone.2025.117600_bb0255","doi-asserted-by":"crossref","DOI":"10.1002\/jbm4.10629","article-title":"Bisphosphonate drug holidays: evidence from clinical trials and real-world studies","volume":"6","author":"Wang","year":"2022","journal-title":"JBMR Plus"},{"issue":"3","key":"10.1016\/j.bone.2025.117600_bb0260","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1007\/s00198-020-05804-3","article-title":"International Osteoporosis Foundation Fracture Working, Vertebral fracture: epidemiology, impact and use of DXA vertebral fracture assessment in fracture liaison services","volume":"32","author":"Lems","year":"2021","journal-title":"Osteoporos. Int."},{"issue":"3","key":"10.1016\/j.bone.2025.117600_bb0265","doi-asserted-by":"crossref","first-page":"246","DOI":"10.11005\/jbm.2024.31.3.246","article-title":"Denosumab in Osteoporosis: Predicting Long-Term Efficacy beyond 10 Years","volume":"31","author":"Lee","year":"2024","journal-title":"J. Bone Metab."},{"issue":"10","key":"10.1016\/j.bone.2025.117600_bb0270","doi-asserted-by":"crossref","first-page":"e1817","DOI":"10.1210\/clinem\/dgae224","article-title":"Zoledronate After Denosumab Discontinuation: Is Repeated Administrations More Effective Than Single Infusion?","volume":"109","author":"Grassi","year":"2024","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.bone.2025.117600_bb0275","doi-asserted-by":"crossref","first-page":"S914","DOI":"10.1016\/j.annonc.2024.08.1545","article-title":"Long term therapy with denosumab and zoledronic acid: A comparative real-world retrospective observational study on skeletal-related events and pain in patients with metastatic breast cancer","volume":"35","author":"Massa","year":"2024","journal-title":"Ann. Oncol."},{"issue":"2","key":"10.1016\/j.bone.2025.117600_bb0280","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1056\/NEJMp1510020","article-title":"Shared decision making--finding the sweet spot","volume":"374","author":"Fried","year":"2016","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.bone.2025.117600_bb0285","doi-asserted-by":"crossref","first-page":"R9","DOI":"10.1093\/ejendo\/lvae076","article-title":"Romosozumab versus parathyroid hormone receptor agonists: which osteoanabolic to choose and when?","volume":"191","author":"Anastasilakis","year":"2024","journal-title":"Eur. J. Endocrinol."}],"container-title":["Bone"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S8756328225002121?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S8756328225002121?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,1,28]],"date-time":"2026-01-28T04:46:10Z","timestamp":1769575570000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S8756328225002121"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11]]},"references-count":57,"alternative-id":["S8756328225002121"],"URL":"https:\/\/doi.org\/10.1016\/j.bone.2025.117600","relation":{},"ISSN":["8756-3282"],"issn-type":[{"value":"8756-3282","type":"print"}],"subject":[],"published":{"date-parts":[[2025,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Treating osteoporosis with denosumab or bisphosphonates in the long term: facts, uncertainties and assumptions. A narrative review by the clinical action group of the European Calcified Tissue Society (ECTS)","name":"articletitle","label":"Article Title"},{"value":"Bone","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bone.2025.117600","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"117600"}}